For DMD caregivers and people with Duchenne, knowing the early signs and next steps can improve self-care and help manage a ...

The Minnesota Department of Health has officially added two more diseases to the list of conditions for which newborns are ...

Italfarmaco S.p.A. today announced a comprehensive update on the regulatory and clinical advancements for givinostat, the ...

An FDA decision on deramiocel for heart muscle disease in DMD is now expected by Aug. 31, after its application was granted ...

Researchers, physicians, families and affected patients view Duchenne muscular dystrophy (DMD) as a neuromuscular condition. Children are diagnosed during the first years of life because they have ...

Surveys of caregivers and health care providers reveal gaps in screening and management of neuropsychiatric and neurodevelopmental symptoms among patients with Duchenne muscular dystrophy in the ...

There is a broad consensus in the medical community in support of Duchenne newborn screening and we in Connecticut are hoping ...

A grandmother is raising awareness of a severe muscle-wasting disease after her grandson was diagnosed with it ...

MDH says early identification and treatment is key to slowing the progression of symptoms as well as extending and improving ...

Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene, leading to muscle degeneration. Current treatments focus on maintaining muscle function, with emerging gene ...

Surveys of caregivers and health care providers reveal gaps in screening and management of neuropsychiatric and neurodevelopmental symptoms among patients with Duchenne muscular dystrophy in the ...

The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of death in DMD patients. DMD is a rare and incurable pediatric ...